4-(4-(piperidin-1-yl)piperidin-1-yl)benzene-1,2-diamine | 882803-25-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(4-(piperidin-1-yl)piperidin-1-yl)benzene-1,2-diamine
• 英文别名: 4-[1,4'-Bipiperidin]-1'-yl-1,2-benzenediamine；4-(4-piperidin-1-ylpiperidin-1-yl)benzene-1,2-diamine
• CAS: 882803-25-0
• 化学式: C₁₆H₂₆N₄
• 分子量: 274.409
• InChiKey: FNHUPGOMKFHTMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  58.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-(piperidin-1-yl)piperidin-1-yl)benzene-1,2-diamine 、 3-醛基吲唑 在 air 作用下， 以 乙醇 、 甲苯 为溶剂， 生成 2-(1H-indazol-3-yl)-5-(4-(piperidin-1-yl)piperidin-1-yl)-1H-benzo[d]imidazole
  参考文献：
  名称：

  Design and structure–activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases

  摘要：

  -3-Benzimidazol-2-yl-1H-indazole analogs were developed as inhibitors of receptor tyrosine kinases (RTK). The synthesis and SAR of this series is reported. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.069
• 作为产物：
  描述：

  4-哌啶基哌啶 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 N-甲基吡咯烷酮 、 乙醇 为溶剂， 反应 6.5h， 生成 4-(4-(piperidin-1-yl)piperidin-1-yl)benzene-1,2-diamine
  参考文献：
  名称：

  Design and structure–activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases

  摘要：

  -3-Benzimidazol-2-yl-1H-indazole analogs were developed as inhibitors of receptor tyrosine kinases (RTK). The synthesis and SAR of this series is reported. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.069

文献信息

• Indazole benzimidazole compounds
  申请人：Chiron Corporation

  公开号：US20030207883A1

  公开（公告）日：2003-11-06

  Organic compounds having the structure I are provided where the variables have the values described herein. 1 Pharmaceutical formulations and medicaments include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compound or a pharmaceutically acceptable salt of the organic compound with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation or medicament according to the invention to a patient in need thereof.

  提供具有结构I的有机化合物，其中变量具有所述的值。1药物制剂和药物包括该有机化合物或其药学上可接受的盐和药学上可接受的载体，并可通过将该有机化合物或其药学上可接受的盐与载体和水混合制备。治疗患者的方法包括向需要该药物的患者施用本发明的药物制剂或药物。
• 3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors
  作者：Christopher M. McBride、Paul A. Renhowe、Thomas G. Gesner、Johanna M. Jansen、Julie Lin、Sylvia Ma、Yasheen Zhou、Cynthia M. Shafer

  DOI：10.1016/j.bmcl.2006.04.043

  日期：2006.7

  The 3-benzimidazol-2-yl-1H-indazole scaffold was developed as an alternate scaffold for our receptor tyrosine kinase (RTK) inhibitor program. In exploring the SAR of this series, it was discovered that a subset of these compounds potently inhibit the enzyme c-ABL. The SAR of these compounds is described. (c) 2006 Elsevier Ltd. All rights reserved.
• INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS
  申请人：CHIRON CORPORATION

  公开号：EP1401831A1

  公开（公告）日：2004-03-31
• US7064215B2
  申请人：——

  公开号：US7064215B2

  公开（公告）日：2006-06-20
• US7642278B2
  申请人：——

  公开号：US7642278B2

  公开（公告）日：2010-01-05